<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730336</url>
  </required_header>
  <id_info>
    <org_study_id>UREC 1524</org_study_id>
    <nct_id>NCT04730336</nct_id>
  </id_info>
  <brief_title>Assessing the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs</brief_title>
  <official_title>Assessment of the Impact of Tixel Treatment of Periorbital Wrinkles on Dry Eye Symptoms and Signs in Patients With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study where effect of standard Tixel treatment as used for periorbital wrinkles would&#xD;
      be assessed on Dry Eye Disease symptoms and signs&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety Assessment will be asses via AE/SAE reporting and Impact Assessment of the effect of&#xD;
      treatment on dry eye symptoms and signs through multiple test indicate Dry Eye&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will undergo three sessions of treatments with the Investigation devise</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NIBUT in Seconds</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Non-Invasive Break Up Time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index questionnaire</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Total 12 questions will be asked, ranked between 0-100. 0 being no dry eye symptoms and 100 severe dry eye symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAFETY, number of AEs</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Any safety related event during the study will be recorded and analyzed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Topography mm D</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Topography with K readings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Exam; Normal, Abnormal</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Multiple Slit Lamp tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standardized Patient Evaluation of Eye Dryness (SPEED) Questionnaire</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Assessment of the frequency and severity of dry eye symptoms. scored 0 to 28; 0 being no dry eye symptoms and 28 severe dry eye symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid margin profile</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Lid margin profile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Sampling Analysis</measure>
    <time_frame>18 Weeks</time_frame>
    <description>ocular tear biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Staining; Total Ocular Staining Score</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Corneal staining fluorescein and conjunctival/lid margin staining lissamine green</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Dry Eye</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Tixel Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tixel Treatment 3 Tixel treatment sessions, 2 weeks apart follow by 2 Follow up sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tixel</intervention_name>
    <description>Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms</description>
    <arm_group_label>Tixel Treatment</arm_group_label>
    <other_name>Fractional</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Mild to Moderate Periorbital wrinkles&#xD;
&#xD;
          -  OSDI score of at least 23&#xD;
&#xD;
          -  Noninvasive Tear film break up time (NIKBUT) ≤ 10 seconds&#xD;
&#xD;
          -  No other eye or skin or immune problems&#xD;
&#xD;
          -  Willing and able to provide written informed consent.&#xD;
&#xD;
          -  Willing to participate in all study activities and instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy and/or breastfeeding&#xD;
&#xD;
          -  Lesions in the periorbital area&#xD;
&#xD;
          -  Acute severe blepharitis&#xD;
&#xD;
          -  Acute conjunctivitis&#xD;
&#xD;
          -  Other concomitant anterior eye disease&#xD;
&#xD;
          -  Has undergone outdoors/sunbed tanning during the last 4 weeks&#xD;
&#xD;
          -  Is unwilling to follow the Tixel aftercare instructions after each of the three Tixel&#xD;
             treatments.&#xD;
&#xD;
          -  Active Herpes Simplex or tendency for Herpes Simplex in the periorbital area (meaning&#xD;
             the subject has had the condition previously).&#xD;
&#xD;
          -  Current skin cancer, malignant sites and/or advanced premalignant lesions or moles in&#xD;
             the treatment area.&#xD;
&#xD;
          -  An impaired immune system condition or use of immunosuppressive medication.&#xD;
&#xD;
          -  Collagen disorders, keloid formation and/or abnormal wound healing.&#xD;
&#xD;
          -  Previous invasive/ablative procedures in the areas to be treated within 3 months prior&#xD;
             to initial treatment or plans for such treatment during the course of the Tixel2&#xD;
             device treatment, or before complete healing of such treatments has occurred.&#xD;
&#xD;
          -  Any patient who takes or has taken any medications (including via topical&#xD;
             application), herbal treatment (oral or topic), food supplements or vitamins, which&#xD;
             may cause fragile skin or impaired skin healing during the last 3 months.&#xD;
&#xD;
          -  Any patient who has used oral Isotretinoin (Accutane® or Roaccutan®) within 3 months&#xD;
             prior to treatment or less.&#xD;
&#xD;
          -  Any patient who has a history of bleeding coagulopathies or use of anticoagulants.&#xD;
&#xD;
          -  Any patient who has tattoos or permanent makeup in the treated area.&#xD;
&#xD;
          -  Any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in&#xD;
             any of the areas to be treated.&#xD;
&#xD;
          -  Any patient who underwent thread lifting of the area to be treated in the last 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Shah, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midland Eye</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sunil Shah, Phd</last_name>
    <phone>+44 121 711 2020</phone>
    <email>s.shah26@aston.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Midland Eye</name>
      <address>
        <city>Solihull</city>
        <zip>B91 2AW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Shah, Phd</last_name>
      <phone>0121 667 3251</phone>
      <email>s.shah26@aston.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

